[17] [18] For patients with combined metabolic concerns including dyslipidemia, this could represent an attractive adjunctive approach
Compounded GLP-1's is available as an injectable or oral formulations
This decline correlates with increases in visceral fat, decreases in lean mass, reduced bone density, and skin thinning
Some of the same factors contributing to low screening rates for CKD are also contributors to low therapy uptake, including treatment inertia, lack of knowledge about guidelines in practice, and concerns regarding insurance coverage and costs
In addition to employer sponsored programs, many companies use workplace giving platforms such as Americas Charity or Network for Good
64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
